PAIN TRIGGERS
Adderall shortages make it hard to obtain certain dosages
Doctors refuse to prescribe boosters or mix stimulants like Vyvanse + Ritalin
App· ADHD patients on Adderall or VyvansePain 7.00/10WTP 5.0/10Market 8.0/10Validation 8.0Confidence 85%Apr 19, 2026
StimFinder: Real-Time ADHD Stimulant Stock Tracker
Adderall shortages result in only 4-5 hours of symptom coverage per day, with popular doses like 20mg XR rarely available at chain pharmacies
adhd-patientscrowd-sourcedhealthcaremedication-shortagemobile-appmonitoringreal-time-alertssaassupply-chain
1
STAGE 01 · PROBLEM
Is the problem real?
CANONICAL PROBLEM
Adderall shortage causing insufficient symptom coverage duration for ADHD patients
FREQUENCY
Multiple repeated complaints in the post and comments.
INTENSITY
Users explicitly describe existing tools as bloated/overkill and mention workaround behavior.
EVIDENCE
Any solutions to Adderall shortage
ADHD23
2
STAGE 02 · CUSTOMER
Who feels this pain?
TARGET USERS
ADHD patients on Adderall or VyvanseA D H D Patients Managing Stimulant Shortages
US ADHD patients on Adderall or Vyvanse facing ongoing shortages
Context
Secure reliable full-day ADHD medication supply and effective dosing during shortages
Switch to less popular dosages like 25mg or 30mg
Call multiple pharmacies, prefer independent 'mom and pop' ones
Current Workarounds
Switch to less popular dosages like 25mg or 30mg
Call multiple pharmacies preferring independent mom-and-pop stores
Maintain backup supplies from prior fills
Seek a new doctor for more flexible prescribing
3
STAGE 03 · MARKET
Where's the gap?
EXISTING SOLUTION GAPS
Adderall unavailable, especially popular doses like 20mg XR
Chain pharmacies (Walgreens, Walmart) unhelpful during shortages
Doctors conservative on combining stimulants despite prior successes
OPPORTUNITY & VALUE
Why Now
Adderall dosage shortages (esp. 20mg) repeatedly mentioned in megathread with availability tips; chain vs. independent pharmacy gaps consistent.
Value Proposition
Hyper-focused on ADHD stimulants with crowd-sourced data from shortage megathreads, avoiding broad pharmacy apps
Product Direction
Mobile app aggregating user-reported real-time stock of ADHD stimulants from independent pharmacies, with alerts for specific doses and locations
4
STAGE 04 · BUSINESS
How does it make money?
MONETIZATION
$4.99/moUnlimited alerts · single user
Model
Freemium mobile app
WILLINGNESS TO PAY
Patients spend hours calling pharmacies daily and prefer independents that chains overlook; signals show repeated frustration with 4-5 hour symptom gaps, equating to high time value where $5/mo saves 5+ hours/week.
5
STAGE 05 · EXECUTION
How do you ship it?
MVP PLAN
“Get Adderall alerts before your symptoms return.”
Mobile app aggregating user-reported real-time stock of ADHD stimulants from independent pharmacies, with alerts for specific doses and locations
Core Features
Search pharmacies by location, dose, and med type (Adderall XR/IR, Vyvanse)
User-reported stock updates with verification prompts
Push notifications for new stock matches
Map view prioritizing independent 'mom and pop' pharmacies
Weekly Roadmap
1
W1-W2
Core stock search and user reporting functional.
- •Build zip-based pharmacy database from public sources
- •Implement user stock report form with photo upload
- •Basic search UI for dose/location
2
W3-W4
Push alerts and verification system live.
- •Add user preferences for dose alerts
- •Firebase push notifications for matches
- •Simple admin moderation for report verification
3
W5
Freemium billing and 100 beta users onboarded.
- •Stripe integration for $4.99/mo premium
- •Internal testing with simulated shortages
- •Recruit 100 r/ADHD beta testers
4
W6
App store launch with first subscribers.
- •iOS/Android submission prep
- •Post MVP case studies in r/ADHD
- •Track 50 paid conversions and retention
Launch Strategy
Launch in Reddit ADHD megathreads (r/ADHD, r/adhdwomen) and X shortage discussions, seed with user tips from comments
RISKS & ASSUMPTIONS
Top Risks
Legal/DEA compliance for controlled substances
Tracking Adderall stock could attract scrutiny if perceived as enabling diversion, requiring strict terms and verification.
Stock data accuracy and freshness
Reliance on user reports or scraping risks false positives/negatives, eroding trust if users drive to empty pharmacies.
User acquisition in regulated health space
App store approval and advertising restrictions for ADHD meds could limit visibility despite strong Reddit signals.
Dependency on ongoing shortages
If FDA resolves Adderall supply issues, pain evaporates, though signals indicate chronic/recurring nature.
6
STAGE 06 · DECISION
Should you build it?
NEED A CLEARER CALL?
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoWhat this score means
This idea scores in the upper-middle range of opportunities surfaced by MonetScope, with a validation sub-score of 8/10 against 1 independently sourced evidence signals. A "promising" rating usually indicates a real pain has been detected and discussed in the open, but the pipeline did not find enough signal to flag it as urgent or high-frequency. These opportunities can still produce excellent businesses — they often correspond to "boring" problems that established players have ignored — but the founder should expect a longer customer-development cycle to confirm willingness to pay.
Why this matters for App founders
It sits at the intersection of "adhd-patients", "crowd-sourced", "healthcare", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. Opportunities in this category typically reward founders who can describe the pain in the user's own language — both because that's the basis of effective marketing, and because it's the strongest signal that the founder has done the upfront listening. The MonetScope pipeline surfaces this category alongside other app signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
Frequently asked questions
Is "StimFinder: Real-Time ADHD Stimulant Stock Tracker" a real validated startup idea or just an AI-generated suggestion?
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
How recent is the underlying data for adhd-patients?
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most app opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
What's the difference between "overall score" and "validation score"?
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.